FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burd	en								
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* GOWEN MAXINE						2. Issuer Name and Ticker or Trading Symbol IDERA PHARMACEUTICALS, INC. [IDRA]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
					ID									X Directo			10% Ov	-	
(Last) (First) (Middle)													Officer below)	(give title		Other (s	specify		
(Last) (First) (Middle) C/O IDERA PHARMACEUTICALS, INC.						3. Date of Earliest Transaction (Month/Day/Year) 06/04/2019								,			,		
505 EAGLEVIEW BLVD., SUITE 212						3.3.3.3.2.3													
						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)	D/		100.41											X Form fi	led by One	Repo	rting Perso	า	
EXTON	PA	1	19341											Form fi Person		e than	One Repor	ting	
(City)	(S	tate)	(Zip)											r cison					
		Tal	ole I - Non	-Deriv	ativ	e Se	curitie	s Ac	quired, [Dis	osed of	f, or Ber	neficial	y Owned					
1. Title of Security (Instr. 3) 2. Transar Date (Month/Date					Execut			Code (In	Transaction Disposed Of (D) (Instr. 3, Code (Instr. 5)			5. Amour Securitie Beneficia Owned F	s ally following	Form (D) or	Ownership orm: Direct O) or Indirect) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
									Code	v	Amount	(A) or (D)	Price	Transact (Instr. 3 a	ion(s)			(III.Ju. 4)	
			Table II - I (uired, Di s, options					Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date		Code (Instr.				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactic (Instr. 4)	s S Ily	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership t (Instr. 4)		
				c	Code	v	(A)	(D)	Date Exercisable		Expiration Date	Title	Amount or Number of Shares						
Stock Option (Right to Buy) ⁽¹⁾	\$2.57	06/04/2019			A		11,500		06/04/2020 ⁽	2)	06/04/2029	Common Stock	11,500	\$0	11,500	0	D		

Explanation of Responses:

- 1. Non-qualified stock options granted, under the Issuer's 2013 Stock Incentive Plan, on the date of the Issuer's 2019 annual meeting of stockholders at an exercise price equal to the closing price of the Issuer's common stock on the date of grant, pursuant to the Issuer's director compensation policy.
- 2. The options vest in full and become immediately exercisable on June 4, 2020 (first anniversary of the date of grant), subject to continued service as a director of the Issuer.

<u>/s/ Maxine Gowen</u> <u>06/06/2019</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.